ARTICLE | Management Tracks
Mendila takes up CDO role at CureVac
Plus: BMS, Merck vet Eid joins Dragonfly and updates from Ariceum, AviadoBio, Poseida and more
February 2, 2023 1:01 AM UTC
Myriam Mendila took up her role as chief development officer at mRNA company CureVac N.V. (NASDAQ:CVAC), an appointment the company announced last June. Mendila succeeds Klaus Edvardsen, who left on June 30, 2022, and interim chief development officer Ulrike Gnad-Vogt.
Immunotherapies company Dragonfly Therapeutics Inc. hired Joseph Eid as president of R&D. Eid led clinical development of Keytruda pembrolizumab at Merck & Co. Inc. (NYSE:MRK) and is a veteran of Bristol Myers Squibb Co. (NYSE:BMY) and Roche (SIX:ROG; OTCQX:RHHBY). Most recently, he was CMO at Luzsana Biotechnology Inc...